Twist and Centogene Collaborate to Make Genetic Testing Rapidly Accessible for More Patients with Rare Diseases

Synthetic DNA maker Twist Bioscience and Centogene, a company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases.

Photo: Andrin Oswald, CEO of Centogene

The resulting products will be designed to make genetic testing more accessible to patients and further drive the understanding of rare diseases. Financial details were not disclosed.

“We are excited to be working together with Twist as we seek to enable the most timely diagnosis for rare disease patients around the world,” said Andrin Oswald, CEO of Centogene. “Not only will this help to provide patients with quicker and more comprehensive answers today, but it will generate insights to advance the precision medicine of tomorrow.”

The product offering will combine Centogene’s rare disease diagnostic expertise powered by the world’s largest bio/databank of its kind with Twist Bioscience’s library preparation and target enrichment capabilities to deliver multiple assays for rare disease diagnosis and analysis. The aim is to increase genetic testing options for the one in 15 individuals that are diagnosed with a rare disease each year. Additionally, the insights generated through these products will augment the bio/databank on rare diseases and may contribute to the discovery and development of novel therapeutics to treat rare diseases in the future.

Author: Rare Daily Staff